FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant

Despite concerns on both safety and efficacy, the FDA approved GlaxoSmithKline’s multiple myeloma drug belantamab mafodotin, deciding that for the sickest patients the benefits outweighed the risk.  It will be marketed as Blenrep and sold for $23,900 per month.